Hold TMO at $605: Stretched technicals with unfavorable entry asymmetry despite confirmed reacceleration thesis
Hold TMO at $605 without adding. The Q2 reacceleration (revenue +10.5%, op income +14.1%) and India structural thesis support the fundamental quality, but stretched technicals (RSI 74.55, upper Bollinger at $614.20, declining volume) create unfavorable entry asymmetry of approximately 1.5% upside vs 3.6-12% downside. Execute tiered protocol: modest starter on shallow dip holding $594-599, larger add at $583-$565, or confirmation add above $614.20 on volume >2.1M. Working stop at 10 EMA ($583); reserve 50 SMA ($522) for tail-risk only. Hard invalidation: close below 200 SMA ($522) on volume signals structural trend break and warrants Underweight downgrade.
| Position | Action |
|---|---|
| Shallow 1-2% dip holding rising 8 EMA / $594-599 breakout zone with positive tape | 25-33% starter position |
| Pullback to $583-$565 with holding price action | 50-75% of intended size |
| Confirmed break above $614.20 on volume >2.1M | 75% with 25% held for retest confirmation |
| Confirmed close above $608.52 with volume | Trim 10-15% to lock in premium |
| Close below $522 (200 SMA) on volume | Hard invalidation - downgrade to Underweight |
TMO is a fortress defensive growth compounder with accelerating earnings, aggressive capital return, and a confirmed uptrend that warrants premium multiple expansion in a flight-to-quality macro environment.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $583.16 | bullish |
| 50 SMA | $521.95 | bullish |
| 200 SMA | $531.43 | bullish |
| MACD Line | +21.45 | bullish |
| MACD Signal | +19.67 | bullish |
| MACD Histogram | +1.78 | bullish |
| RSI (14) | 74.55 | bullish |
| Bollinger Upper Band | $614.20 | neutral |
| Bollinger Middle Band (20 SMA) | $564.32 | neutral |
| Bollinger Lower Band | $514.44 | neutral |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $583-$565 with holding price action
Then: Add 50-75% of intended size
Forward P/E of ~22x is fair for a business in mid-cycle recovery with 48% expected earnings rebound
↩ rebuts: “Bear claims 32.5x trailing P/E is expensive”
Quality at $605 is not a buy—after a 38% rally with RSI at 74.55, elevated leverage, $54.8B in goodwill, and negative net tangible assets, the risk/reward is asymmetric to the downside and the bull's own research stack says HOLD.
· concedes: TMO is a quality company—nobody disputes that; The catalyst pipeline is real; The acquisition could work if synergies materialize; The technical setup could extend if institutional flow continues; The bear case is about timing and price, not the fundamental thesis
→ vs conservative: RSI at 74.55 is a textbook rookie mistake — RSI can stay overbought for weeks in real trends; risk/reward math anchored to $605 entry is already behind us
→ vs conservative: Volume at 1.35M vs 2.1M average is normal mid-trend behavior; volume doesn't need to blow out every day when structure is intact
→ vs conservative: $583 entry target is roughly 3.7% below current — with $16 ATR and 10 EMA rising ~$1.50/week, that pullback may never come or reverse in two sessions
→ vs neutral: Sentiment of 6.2/10 mildly bullish with low confidence because retail was quiet is actually a feature — institutional accumulation without froth is the cleanest tape
→ vs neutral: Uniformly constructive news flow (FDA clearances, India expansion, peer beats from Labcorp and BDX) confirms the thesis — not a reason for low confidence
| $16.00 |
| neutral |
| Volume (2026-08-11) | 1.35M | neutral |
Support: 514.44 · 521.95 · 531.43 · 583.16 | Resistance: 605 · 614.2
TMO is in a powerful medium-term uptrend that emerged from an oversold base in mid-May 2026, with price ($605.00) sitting comfortably above all key moving averages and momentum indicators confirming bullish regime (MACD crossed positive on 2026-06-23 and reached +21.45; RSI climbed from 33.17 to 74.55). The 50 SMA has risen from $473.06 (2026-06-12) to $521.95, demonstrating a ~10% slope over two months, and has recently crossed above the 200 SMA. However, the move is now extended—RSI is overbought and price is approaching the upper Bollinger Band ($614.20)—suggesting a pullback to the rising 10 EMA ($583.16) would be a healthier entry. ATR has expanded to $16 (from ~$14), requiring wider stops (~2×ATR = $32). Recommendation: HOLD with tactical buy-on-pullback bias; existing holders should trail stops to the 10 EMA area.
Market Cap
$223.70B
52-Week High
$643.99
52-Week Low
$435.27
50-Day Moving Average
$519.80
200-Day Moving Average
$532.02
Beta
0.847
Dividend Yield
0.31%
P/E Ratio (TTM)
32.54x
Forward P/E
21.99x
PEG Ratio
1.96
Price/Book
4.25x
EPS (TTM)
$18.59
Forward EPS
$27.51
Revenue (TTM)
$46.34B
Gross Profit (TTM)
$18.99B
EBITDA (TTM)
$11.74B
Net Income (TTM)
$6.97B
Return on Equity (ROE)
13.52%
Return on Assets (ROA)
5.13%
Total Assets
$113.17B
Total Equity
$52.68B
Book Value/Share
$142.47
Total Debt
$42.55B
Net Debt
$38.49B
Cash & Equivalents
$4.06B
Goodwill
$54.83B
Current Ratio
1.551
Debt/Equity
80.6%
Working Capital
$8.30B
Net Tangible Assets
($20.76B)
Net Debt/EBITDA
3.28x
OCF (Q2 2026)
$2.13B
FCF (Q2 2026)
$1.68B
FCF (TTM)
$6.24B
FCF Yield
~2.79%
CapEx (Q2 2026)
$0.45B
Q2 2026 Revenue
$11.99B
Q2 2026 Operating Income
$2.19B
Q2 2026 Net Income
$1.74B
Q2 2026 Diluted EPS
$4.68
Q2 2026 Gross Margin
40.7%
Q2 2026 Operating Margin
18.2%
Q2 2026 Net Margin
14.5%
Revenue Growth (Q2 YoY)
+10.5%
EPS Growth (Q2 YoY)
+9.3%
Share Count (Q2 2026)
369.7M
Interest Expense (Q2 2026)
$401M
Strengths
Concerns
Thermo Fisher Scientific (TMO) is a best-in-class healthcare equipment company with a fortress balance sheet and premium margins (40%+ gross, 26%+ EBITDA) generating $6.2B+ in annual free cash flow. The stock appears expensive at 32.5x trailing P/E but reasonable at 22x forward P/E given the expected 48% EPS recovery to $27.51, supported by Q2 2026's 10.5% revenue growth and 9.3% EPS growth. While elevated leverage (3.3x Net Debt/EBITDA) following a ~$8.9B Q1 2026 acquisition is a concern, robust FCF generation and investment-grade ratings support debt service. The 0.31% dividend yield is nominal; TMO is a total-return story driven by capital appreciation and buybacks, warranting a HOLD rating for long-term investors with preference for accumulating on pullbacks toward $532.
Macro: Risk-off macro environment with US equities fading for a second consecutive session (Aug 11) driven by rising oil and CPI anticipation. Crypto also under pressure (BTC < $64K). Prediction markets show 86% probability of no Fed cuts in 2026, with US recession probability at 8% (down 1pp), UK recession at 18% (up 3.5pp), and Japan recession at 34% (up 4pp). July Core CPI distribution is clustered around 0.2% MoM (54% probability, up 2.9pp) and 2.4% YoY (44% probability, up 16pp)—combined probability of ≤0.2% MoM is approximately 84%, consistent with disinflation continuing toward but not below the 2% target without forcing emergency cuts.